SCHEMBL2967113

SCHEMBL2967113

CNC(=O)COC(=O)NCCC1CCN(Cc2cccc(Oc3ccc(F)cc3)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 9/20 0.54
CCR8 P51685 4/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2975693 0.87 CHRM4 (0.60) CHRM4
SCHEMBL27654951 0.86 CHRM4 (0.50) CHRM4CCR8MEN1KMT2A
SCHEMBL2983017 0.86 CHRM4 (0.50) CHRM4BCHEACHE
SCHEMBL2979451 0.85 CHRM4 (0.48) CHRM4ACHE
SCHEMBL3938451 0.85 CHRM4 (0.65) CHRM4CCR8BCHEACHE
SCHEMBL2979849 0.83 CHRM4 (0.56) CHRM4
SCHEMBL2979043 0.81 ACHE (0.52) CHRM4BCHEACHE
SCHEMBL2977698 0.80 FAAH (0.48) CHRM4BCHEACHE
SCHEMBL2982148 0.79 CACNA1G (0.46) CHRM4
SCHEMBL2974298 0.79 CHRM2 (0.58) CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
US-7781590-B2 Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
CN-1921858-A Piperidinylalkylcarbamate derivatives, process for their preparation and their use as FAAH enzyme inhibitors SANOFI AVENTIS (FR) 2007-02-28 CN disclosed
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 CHRM4 2647/4885CCR8 2783/4885MEN1 4752/4885
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 CHRM4 2788/4885CCR8 2508/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.